Key result
Smooth muscle CXCL12 ablation in mice causes ~50% embryonic lethality and cardiac defects, attenuated by TC14012.
Why the study?
CXCL12 is linked to cardiovascular development and coronary disease, but its cell- and tissue-specific effects remain poorly understood.
Does the CXCR7 agonist TC14012 attenuate cardiac hypertrophy in SM-CXCL12−/− mice?
Does the CXCR7 agonist TC14012 attenuate cardiac hypertrophy in SM-CXCL12−/− mice?
Smooth muscle-specific CXCL12 is critical for coronary artery development and preventing cardiac hypertrophy, and pharmacological stimulation of its co-receptor CXCR7 may offer a therapeutic target to attenuate adverse hypertrophic remodeling.
Answers are grounded in this paper and cite their sources.
CXCR7 agonism attenuates hypertrophy in this murine model; leaves open translation to human cardiac disease.
The chemokine CXCL12 plays a fundamental role in cardiovascular development, cell trafficking, and myocardial repair. Human genome-wide association studies even have identified novel loci downstream of the CXCL12 gene locus associated with coronary artery disease and myocardial infarction. Nevertheless, cell and tissue specific effects of CXCL12 are barely understood. Since we detected high expression of CXCL12 in smooth muscle (SM) cells, we generated a SM22-alpha-Cre driven mouse model to ablate CXCL12 (SM-CXCL12−/−). SM-CXCL12−/− mice revealed high embryonic lethality (50%) with developmental defects, including aberrant topology of coronary arteries. Postnatally, SM-CXCL12−/− mice developed severe cardiac hypertrophy associated with fibrosis, apoptotic cell death, impaired heart function, and severe coronary vascular defects characterized by thinned and dilated arteries. Transcriptome analyses showed specific upregulation of pathways associated with hypertrophic cardiomyopathy, collagen protein network, heart-related proteoglycans, and downregulation of the M2 macrophage modulators. CXCL12 mutants showed endothelial downregulation of the CXCL12 co-receptor CXCR7. Treatment of SM-CXCL12−/− mice with the CXCR7 agonist TC14012 attenuated cardiac hypertrophy associated with increased pERK signaling. Our data suggest a critical role of smooth muscle-specific CXCL12 in arterial development, vessel maturation, and cardiac hypertrophy. Pharmacological stimulation of CXCR7 might be a promising target to attenuate adverse hypertrophic remodeling.
No takes yet. Share an insight, caveat, or question.
Ghadge et al. (2021) studied Cardiac hypertrophy and coronary artery defects. Smooth muscle-specific ablation of CXCL12 / CXCR7 agonist TC14012 was evaluated on Embryonic lethality and developmental defects. Smooth muscle-specific ablation of CXCL12 in mice caused 50% embryonic lethality, severe cardiac hypertrophy, and coronary vascular defects, which were attenuated by the CXCR7 agonist TC14012.
Synapse has enriched 10 related papers. Consider them for comparative context: